TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10957827

Group type: EXPERIMENTAL
Intervention: Increased intolerance of uncertainty (gambling procedure)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Decreased intolerance of uncertainty (gambling procedure)
Number of subjects: 42
Study: 8781791

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (Medimix) in 50% oxygen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pethidine hydrochloride 1 mg/kg
Number of subjects: 38
Study: 1377311

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Laser photoablation
Number of subjects: 23
Study: 6143815

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Temazepam 30 mg with Cimetidine 300 mg every 6 h
Number of subjects: 9
Study: 31829170

Group type: EXPERIMENTAL
Intervention: Ultra-fast-track anesthesia (UFTA)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional anesthesia
Number of subjects: 194
Study: 30428403

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa followed by hp-hMG
Number of subjects: 234

Group type: COMPARATOR
Intervention: hp-hMG
Number of subjects: 234
Study: 27338674

Group type: COMPARATOR
Intervention: Closed reduction using Ash forceps
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Septoplasty surgery
Number of subjects: 30
Study: 23975477

Group type: EXPERIMENTAL
Intervention: HIV/HCV prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22339483

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 45-450 μg single intranasal doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 120 μg three times daily for 15 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 120 μg three times daily for 5 days with a final single dose on day 7
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide (BCQB) 45, 90, and 180 μg single intranasal doses
Number of subjects: 10
Study: 20483156

Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 2784
Study: 18028196

Group type: EXPERIMENTAL
Intervention: Improved mechanical oral hygiene
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Antibacterial mouth rinse (amine and stannous fluoride)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combination of intensive mechanical and antibacterial measures
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group with no specific regimen
Number of subjects: 106
Study: 16275600

Group type: EXPERIMENTAL
Intervention: Naloxone (10 ng/mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-current-density electrical stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Naloxone (0.1, 1 ng/mL)
Number of subjects: 15
Study: 11972485

Group type: EXPERIMENTAL
Intervention: Benzydamine
Number of subjects: 137
Study: 10865160

Group type: EXPERIMENTAL
Intervention: Underage drinking
Number of subjects: 7061

Group type: EXPERIMENTAL
Intervention: Residence in a fraternity or sorority
Number of subjects: 7061

Group type: EXPERIMENTAL
Intervention: Very easy access to alcohol
Number of subjects: 7061

Group type: EXPERIMENTAL
Intervention: Obtaining drinks at lower prices (under $1 each or a set fee for unlimited drinks)
Number of subjects: 7061

Group type: EXPERIMENTAL
Intervention: Drinking beer
Number of subjects: 7061
Study: 9036717

Group type: EXPERIMENTAL
Intervention: Parenteral gold
Number of subjects: 358
Study: 1462864

Group type: EXPERIMENTAL
Intervention: 1800 U glandular kallikrein orally for 5 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1800 U glandular kallikrein orally for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1800 U glandular kallikrein orally
Number of subjects: 100
Study: 4091992

Group type: EXPERIMENTAL
Intervention: oral solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: retard capsule
Number of subjects: 12
Study: 31548894

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 3 days
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126
Study: 29428315

Group type: EXPERIMENTAL
Intervention: High testosterone (T) and high antimüllerian hormone (AMH)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Norm testosterone (T) and norm antimüllerian hormone (AMH)
Number of subjects: 1198
Study: 27609813

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (ICBT)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Number of subjects: 945

Group type: COMPARATOR
Intervention: Usual care by a physician
Number of subjects: 945
Study: 24346596

Group type: EXPERIMENTAL
Intervention: DTaP5‐IPV‐Hib‐HepB plus PCV7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP5‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentavalent DTaP5‐IPV/Hib plus HepB plus PCV7
Number of subjects: 0
Study: 23390790

Group type: EXPERIMENTAL
Intervention: Adjustable toe splint for 2 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (proper shoes only)
Number of subjects: 36
Study: 20733439

Group type: EXPERIMENTAL
Intervention: Desipramine tablets - placebo cream
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lidocaine cream - placebo tablet
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo tablets - placebo cream
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lidocaine cream - desipramine tablet
Number of subjects: 133

Group type: COMPARATOR
Intervention: Desipramine tablets
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lidocaine cream
Number of subjects: 133
Study: 18575435

Group type: EXPERIMENTAL
Intervention: Anterior decompression approach using cervical retractor systems (Group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional surgical approach (Group A)
Number of subjects: 92
Study: 15902988

Group type: EXPERIMENTAL
Intervention: Cold water condition (20 degrees)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neutral water condition (33 degrees)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Resting condition
Number of subjects: 11
Study: 12905545

Group type: EXPERIMENTAL
Intervention: Consultant-led group
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Open access group
Number of subjects: 1131
Study: 10076944

Group type: EXPERIMENTAL
Intervention: Anterior knee pain syndrome patients (12 knees)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy volunteers (20 knees)
Number of subjects: 10
Study: 7585852

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide 220 micrograms plus placebo capsule
Number of subjects: 298

Group type: COMPARATOR
Intervention: Oral loratadine 10 mg plus placebo nasal spray
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 298

Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 298
Study: 2258355

Group type: EXPERIMENTAL
Intervention: pefloxacin 400 mg iv
Number of subjects: 162

Group type: COMPARATOR
Intervention: cefazolin 1.0 g iv
Number of subjects: 162
Study: 7000172

Group type: EXPERIMENTAL
Intervention: Timolol maleate (Timoptol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30982092

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program (exercise, behaviour change, symptom management)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study: 30877937

Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer-coated biolimus-eluting stent (BP-BES)
Number of subjects: 4255

Group type: COMPARATOR
Intervention: Durable-polymer-coated drug-eluting stents (DP-DES)
Number of subjects: 4255
Study: 27776936

Group type: EXPERIMENTAL
Intervention: Compliance-guided PEEP
Number of subjects: 70

Group type: COMPARATOR
Intervention: FiO2-guided PEEP
Number of subjects: 70
Study: 26314702

Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg of the participant's body mass, to a maximum of 2.5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study: 23442944

Group type: EXPERIMENTAL
Intervention: Maintenance clopidogrel
Number of subjects: 6327
Study: 21196617

Group type: EXPERIMENTAL
Intervention: Spironolactone 25‐50 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 19480864

Group type: EXPERIMENTAL
Intervention: Modified acupuncture therapy with needle insertion into multiple loci to elicit local twitch responses at acupuncture points Wai‐guan and Qu‐chi.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham acupuncture.
Number of subjects: 20
Study: 16979835

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) and intraoperative electron‐beam radiation therapy (IOERT) with preoperative or postoperative chemoradiation (CRT)
Number of subjects: 210
Study: 15283927

Group type: EXPERIMENTAL
Intervention: 2.5 mg per day tibolone (OD, n = 18)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: daily combined 0.625 mg of conjugated estrogens 2.5 mg-1 of medroxy progesterone acetate pill (EP, n = 20)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vitamin pill (C, n= 20)
Number of subjects: 58
Study: 11275387

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (12-week trial)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Surface electromyographic biofeedback (12-week trial)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vestibulectomy
Number of subjects: 78

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 78
Study: 9606845

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 8024627

Group type: EXPERIMENTAL
Intervention: New tablet formulation of sotalol hydrochloride (80 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard preparation of sotalol hydrochloride
Number of subjects: 16
Study: 2689911

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 2

Group type: COMPARATOR
Intervention: Succinylcholine-pancuronium
Number of subjects: 2
Study: 949645

Group type: EXPERIMENTAL
Intervention: Dexon sutures
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 87
Study: 31451942

Group type: EXPERIMENTAL
Intervention: PhysioQuiz mobile app
Number of subjects: 489
Study: 28588165

Group type: EXPERIMENTAL
Intervention: Eptifibatide (10 mg intra coronary single bolus dose)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control (no eptifibatide)
Number of subjects: 146
Study: 25921451

Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg/d via eRapid nebulizer
Number of subjects: 87
Study: 23406890

Group type: EXPERIMENTAL
Intervention: Talking Parents, Healthy Teens program (8 weekly 1-hour sessions)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Talking Parents, Healthy Teens program
Number of subjects: 535
Study: 21965486

Group type: EXPERIMENTAL
Intervention: Provider activation through electronic dental records (EDRs)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patient activation through personal health records
Number of subjects: 102
Study: 19589146

Group type: EXPERIMENTAL
Intervention: lafutidine 10 mg with mosapride 5 mg
Number of subjects: 10
Study: 20084717

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based hepatic arterial infusion (HAI) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study: 14995946

Group type: EXPERIMENTAL
Intervention: 7.5% NaCl infusion (4 ml kg‐1 over 10 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% NaCl infusion (control)
Number of subjects: 20
Study: 11709597

Group type: EXPERIMENTAL
Intervention: Computer-aided learning (CAL) programme
Number of subjects: 85

Group type: COMPARATOR
Intervention: Lecture and seminar on IOTN
Number of subjects: 85
Study: 10084352

Group type: EXPERIMENTAL
Intervention: Religious‐sociocultural psychotherapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 203
Study: 7997323

Group type: EXPERIMENTAL
Intervention: oral acyclovir (400 mg 5 times daily, n = 51)
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo (n = 53)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: oral acyclovir (400 mg 5 times daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study: 3180119

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0
Study: 29458932

Group type: EXPERIMENTAL
Intervention: Arsenicum album 30cH (6 doses, thrice daily for two days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (indistinguishable from verum)
Number of subjects: 120
Study: 28104514

Group type: EXPERIMENTAL
Intervention: RGI-2001
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (nonresponders)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 29
Study: 25799130

Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 98
Study: 23035721

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 20375503

Group type: EXPERIMENTAL
Intervention: Spine surgery under general anesthesia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spine surgery patients without new-onset AD
Number of subjects: 10
Study: 18509559

Group type: EXPERIMENTAL
Intervention: Single home visit by an occupational therapist
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no home visit)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 95
Study: 16579718

Group type: EXPERIMENTAL
Intervention: Self-focus group (viewing themselves on a TV monitor)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Monitoring group (instructed to focus on their thoughts, body sensations, mood, and performance)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No instruction group
Number of subjects: 51
Study: 12971703

Group type: EXPERIMENTAL
Intervention: D-amphetamine (10 mg every fourth day, totalling 100 mg in 36 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10702432

Group type: EXPERIMENTAL
Intervention: Modified left double-lumen tube (L-DLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Right double-lumen tube (R-DLT)
Number of subjects: 40
Study: 9088593

Group type: EXPERIMENTAL
Intervention: Prototype DPI (2 x 100 micrograms salbutamol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: MDI (Ventolin, 2 x 100 micrograms salbutamol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prototype DPI
Number of subjects: 10

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 10
Study: 7880370

Group type: EXPERIMENTAL
Intervention: Karaya-based barrier
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pectin-based barrier
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Type of tape used
Number of subjects: 112
Study: 3066240

Group type: EXPERIMENTAL
Intervention: Propofol (PF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propanidid (PD)
Number of subjects: 40
Study: 29266773

Group type: EXPERIMENTAL
Intervention: Myb28B/B broccoli soup
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Myb28B/V broccoli soup
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Myb28V/V broccoli soup
Number of subjects: 10

Group type: COMPARATOR
Intervention: All broccoli genotypes
Number of subjects: 10
Study: 28778219

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches starting at 5 μg/h, titrated to a maximum of 40 μg/h over 6 weeks, continued for 11 weeks.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches
Number of subjects: 114
Study: 26684994

Group type: EXPERIMENTAL
Intervention: Immersive Visualization (IV) eyewear during oral debridement (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immersive Visualization (IV) eyewear during oral debridement (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined mean calmness scores for both groups
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline DAS‐R anxiety levels for Group A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline DAS‐R anxiety levels for Group B
Number of subjects: 30
Study: 24107473

Group type: EXPERIMENTAL
Intervention: PiP intervention (outdoor playground-based physical activity intervention)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control arm (usual practice)
Number of subjects: 150
Study: 21236234

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve BBG-01
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18334706

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with PELF (cisplatin 40 mg/m² on days 1 and 5, epirubicin 30 mg/m² on days 1 and 5, L-leucovorin 100 mg/m² on days 1-4, and 5-fluorouracil 300 mg/m² on days 1-4)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 258
Study: 17190893

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/d
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Alendronate (both doses)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 1099
Study: 14610129

Group type: EXPERIMENTAL
Intervention: Symptomatic CH patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CH patients in remission
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 10
Study: 10731626

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg iv)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDMA (1.5 mg/kg po)
Number of subjects: 16
Study: 9363712

Group type: EXPERIMENTAL
Intervention: Intracervical insemination by straw
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cervical cap with intracervical reservoir
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cervical cap
Number of subjects: 91
Study: 1543796

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3085428

Group type: EXPERIMENTAL
Intervention: 15 mg diazepam orally
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 mg diazepam as a rectal solution
Number of subjects: 100
Study: 29475121

Group type: EXPERIMENTAL
Intervention: True indoor air filtration
Number of subjects: 70
Study: 27891830

Group type: EXPERIMENTAL
Intervention: Genetic risk
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Lifestyle risk
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Combined genetic/lifestyle risks
Number of subjects: 696

Group type: COMPARATOR
Intervention: No risk information (control)
Number of subjects: 696
Study: 23313811

Group type: EXPERIMENTAL
Intervention: epratuzumab 2400 mg cumulative dose (600 mg weekly)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: epratuzumab 2400 mg cumulative dose (1200 mg EOW)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: epratuzumab 2400 mg cumulative dose (all patients)
Number of subjects: 227

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 227
Study: 24362859

Group type: EXPERIMENTAL
Intervention: Peer-led smoking prevention intervention with extracurricular activities including the 'Smoking Prevention Tour' (4-hour activity) and 'Smoke-free Schools' intervention.
Number of subjects: 2476

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 2476
Study: 20024491

Group type: EXPERIMENTAL
Intervention: In vivo rFVIIa administration (45, 90, or 180 microg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ex vivo rFVIIa spiking (0.6, 1.2, or 2.4 microg/ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ROTEM and TEG analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: In vivo rFVIIa administration
Number of subjects: 30
Study: 18786111

Group type: EXPERIMENTAL
Intervention: CDAI decrease by > or =70 points for the last two consecutive visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDAI decrease in baseline by > or =100 points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDAI decrease by 50, 70, 100, or 150 points; decrease by 25% from baseline and by 70 or 100 points; CDAI <100 or 150 points; CDAI <150 points plus decrease by 70 or 100 points; CDAI <150 points at any time sustained for the duration of the trial; or decrease in the CDAI by 70 points for the last two consecutive visits
Number of subjects: 0
Study: 15831652

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 1683
Study: 12851352

Group type: EXPERIMENTAL
Intervention: Plantar fascia tissue-stretching program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Achilles tendon-stretching program
Number of subjects: 101
Study: 10482309

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8582958

Group type: EXPERIMENTAL
Intervention: 5000 IU HCG subcutaneously (s.c.)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10,000 IU HCG subcutaneously (s.c.)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 5000 IU HCG intramuscularly (i.m.)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 10,000 IU HCG intramuscularly (i.m.)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 5000 IU HCG
Number of subjects: 104

Group type: COMPARATOR
Intervention: 10,000 IU HCG
Number of subjects: 104
Study: 1720834

Group type: EXPERIMENTAL
Intervention: Felodipine ER, 10 mg once daily for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ), 25 mg once daily for 2 weeks
Number of subjects: 28
Study: 6174913

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin eye drops
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neomycin-polymyxin-gramicidin eye drops
Number of subjects: 48
Study: 31692001

Group type: EXPERIMENTAL
Intervention: Ethyl acetate extract
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Petroleum ether extract
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Validation of spectral effect relationship
Number of subjects: 43